WONDERS 2 Study
Infectious Diseases
WONDERS 2 Study: Exploring a Once-Weekly HIV Treatment Option
The WONDERS 2 Study is a Phase 2/3 clinical trial being conducted by Wits RHI to assess the safety and efficacy of a novel once-weekly oral HIV-1 treatment regimen in people who have never received antiretroviral therapy (ART). The study evaluates whether a combination of GS-1720 (an integrase strand-transfer inhibitor) and GS-4182 (a lenacapavir prodrug) can be a viable alternative to daily HIV treatment.
Objectives
- Evaluate if a once-weekly regimen is as effective as the daily Biktarvy® (bictegravir/emtricitabine/tenofovir alafenamide) standard-of-care.
- Measure viral suppression (HIV-1 RNA <50 copies/mL), CD4 cell recovery, and safety.
- Understand treatment satisfaction and long-term tolerability.
Who Can Participate
Adults (18+) living with HIV-1 who:
- Are treatment-naïve
- Have HIV-1 RNA ≥500 copies/mL
- Have CD4 ≥200 cells/mm³
Individuals who have taken long-acting injectables or have active hepatitis or TB are not eligible.
Latest Update
April 2025
For more information about WONDERS 2 Study, please email rhicomms@wrhi.ac.za.
